Cargando…

Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases

Cancer is a leading causes of death. Despite significant success in the treatment of lymphatic system tumors, the problems of relapse, drug resistance and effectiveness of therapy remain relevant. Oncolytic viruses are able to replicate in tumor cells and destroy them without affecting normal, healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Vorobyev, P. O., Babaeva, F. E., Panova, A. V., Shakiba, J., Kravchenko, S. K., Soboleva, A. V., Lipatova, A. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pleiades Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534467/
https://www.ncbi.nlm.nih.gov/pubmed/36217339
http://dx.doi.org/10.1134/S0026893322050144
Descripción
Sumario:Cancer is a leading causes of death. Despite significant success in the treatment of lymphatic system tumors, the problems of relapse, drug resistance and effectiveness of therapy remain relevant. Oncolytic viruses are able to replicate in tumor cells and destroy them without affecting normal, healthy tissues. By activating antitumor immunity, viruses are effective against malignant neoplasms of various nature. In lymphoproliferative diseases with a drug-resistant phenotype, many cases of remissions have been described after viral therapy. The current level of understanding of viral biology and the discovery of host cell interaction mechanisms made it possible to create unique strains with high oncoselectivity widely used in clinical practice in recent years.